Guardant Health: Q3 Earnings Snapshot
Guardant Health reported a Q3 loss of $124.4 million, or 93 cents per share, matching analyst expectations. Adjusted losses were 29 cents per share. Revenue was $361 million, exceeding forecasts of $350.8 million. The company expects full-year revenue between $1.36 billion and $1.37 billion.
How this was made
The 30-second read
Why it matters
The mixed earnings result may cause a modest pullback in GH stock, with attention on full‑year revenue guidance.
Market read
First‑time Q3 earnings release with new financial figures, relevant for biotech investors.
What to watch
Guidance of $1.36‑$1.37B suggests potential upside if the company improves margins.
Background
Guardant Health provides oncology testing services; its earnings are closely watched for the liquid biopsy market.
Ticker impact
Guardant Health reported Q3 loss of $124.4M and revenue of $361M, beating estimates.
likely slight pressure as market prices in the loss despite revenue beat
Losses were larger than expected on a per‑share basis, while revenue only modestly exceeded forecasts, leading to mixed reaction.
Market effects
Biotech earnings season may influence peer valuations.
US biotech sector sees modest movement.
Limited to investors tracking oncology testing firms.
Counterpoint
Revenue beat could support a short‑term rally if investors focus on top‑line growth.
Key entities
- CompanyGuardant Health Inc.
Provider of oncology testing services.
